InvestorsHub Logo
Followers 369
Posts 17907
Boards Moderated 3
Alias Born 04/02/2009

Re: None

Monday, 11/11/2013 5:57:40 PM

Monday, November 11, 2013 5:57:40 PM

Post# of 6072
Spectrum Pharmaceuticals to Present Corporate Update at the Credit Suisse 2013 Healthcare Conference in Arizona on November 1...
Date : 11/11/2013 @ 7:00AM
Source : Business Wire
Stock : Spectrum Pharmaceuticals, Inc. (MM) (SPPI)
Quote : 9.42 0.0 (0.00%) @ 5:29PM

Spectrum Pharmaceuticals to Present Corporate Update at the Credit Suisse 2013 Healthcare Conference in Arizona on November 1...
Print
Alert
Spectrum (NASDAQ:SPPI)
Intraday Stock Chart

Today : Monday 11 November 2013
Click Here for more Spectrum Charts.

Spectrum Pharmaceuticals (Nasdaq: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Credit Suisse 2013 Healthcare Conference being held at the Phoenician in Scottsdale, Arizona. The Company presentation is on Wednesday, November 13, 2013, at 3:00 PM MT.

A live webcast of Spectrum's presentation will be available at http://www.sppirx.com.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum and its affiliates market four oncology drugs - FUSILEV® (levoleucovorin) for Injection in the U.S.; FOLOTYN® (pralatrexate injection), also marketed in the U.S.; ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights and MARQIBO® (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion, for which the Company has worldwide marketing rights. Spectrum's strong track record in in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.